ELISA News and Research

RSS

New assay improves detection of SARS-CoV-2 antibodies

Researchers at the University of California Santa Cruz have developed a new assay for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that they say provides significant advantages over the techniques currently used.

20 Jul 2020

China's Ad5 vectored COVID-19 vaccine safe and induces immune response

A phase 2 trial of an Ad5 vectored COVID-19 vaccine candidate, conducted in China, has found that the vaccine is safe and induces an immune response, according to new research published in The Lancet.

20 Jul 2020

Oxford University and AstraZeneca vaccine against SARS-CoV-2 safe and induces immune response

Promising early stage results from a phase 1/2 clinical trial of the UK's vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) are published today in The Lancet.

20 Jul 2020

Game-Changer: A SARS-CoV-2 serological test for 50-cents per sample!

A recent study published in the preprint server medRxiv in July 2020 shows that this is indeed possible. The development of this inexpensive but reliable and sensitive test could change the face of preventive measures for COVID-19 in low-resource settings.

17 Jul 2020

Children with MIS-C have different antibody responses than adults with COVID-19

A new study published on the preprint medRxiv in July 2020 reveals that children with the condition Multisystem Inflammatory Syndrome in Children (MIS-C) have a distinctly different pattern of antibody generation compared to adults with COVID-19 disease.

16 Jul 2020

Study finds significant variability in the accuracy of currently available COVID-19 antibody tests

A new peer-reviewed study by researchers at NSF International and Novateur Ventures finds significant variability in the accuracy of currently available COVID-19 antibody tests.

15 Jul 2020

BATM introduces three new diagnostic kits for COVID-19 and other respiratory illness

BATM, a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces the launch of three new diagnostic kits to significantly advance the diagnosis of COVID-19 and other respiratory illnesses.

15 Jul 2020

Cold sensitivity of SARS-CoV-2 could impact vaccine studies

Researchers at Duke University in Durham, USA, have made an important discovery about the spike protein on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have a broad impact on vaccine studies.

14 Jul 2020

Serology distinguishes children with MIS-C associated with COVID-19

Researchers in the United States say that measuring antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may help to distinguish between multisystem inflammatory syndrome in children (MIS-C) and other clinically similar syndromes.

13 Jul 2020

Dutch trial of convalescent plasma in COVID-19 discontinued

Now, a recent trial published on the preprint server medRxiv* in July 2020 reports that a majority of hospitalized COVID-19 patients have a high titer of neutralizing antibodies, at the time of admission, within 10 days of symptomatic disease.

7 Jul 2020

COVID-19 study in Italian town reveals the importance of asymptomatic cases

A study of COVID-19 in the quarantined Italian town of Vò, where most of the population was tested, reveals the importance of asymptomatic cases.

30 Jun 2020

Brazilian startup to develop a low-cost high-performance COVID-19 diagnostic test

Researchers at Biolinker, a biotech startup based in São Paulo, Brazil, are developing a low-cost high-performance COVID-19 diagnostic test using only locally sourced inputs.

26 Jun 2020

BATM provides business and trading update

BATM, a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following business and trading update.

26 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

23 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

A highly sensitive and specific antibody test for COVID-19

A new proof-of-concept study by UK researchers, currently available on the medRxiv* preprint server, describes the development of an enzyme-linked immunosorbent assay that can be used when lower levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific-antibodies are present in serum and saliva samples.

21 Jun 2020